Acute Renal Failure (ARF) Market Report 2026

Acute Renal Failure (ARF) Market Overview

• Acute Renal Failure (ARF) market size has reached to $6.6 billion in 2025 • Expected to grow to $9.71 billion in 2030 at a compound annual growth rate (CAGR) of 8% • Growth Driver: Increasing Prevalence Of Chronic Kidney Diseases Is Driving Growth • Market Trend: Regulatory Approvals For Acute Kidney Injury Drug Development • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Acute Renal Failure (ARF) Market?

Acute renal failure (ARF), also known as acute kidney injury (AKI), refers to a sudden and rapid decline in kidney function over a period of hours or days. Acute renal failure is treated through various methods, including medication, fluid management, and dialysis, to help restore kidney function and prevent further complications. The main types of disease in acute renal failure (ARF) are prerenal acute renal failure, renal acute renal failure, and postrenal acute renal failure. Prerenal acute renal failure occurs due to factors affecting blood flow to the kidneys, such as dehydration or heart failure. The various drug types include diuretics, vasopressors, erythropoiesis-stimulating agents (ESAs), phosphate binders, calcium and vitamin D supplements, antibiotics, and other drugs. These are used for various routes of administration, including oral and intravenous. The various diagnoses include computed tomography (CT) scans, kidney biopsies, and ultrasounds and are used by various end users, such as clinics, hospitals, home healthcare, and others.

What Is The Acute Renal Failure (ARF) Market Growth Forecast?

The acute renal failure (arf) market size is expected to see strong growth in the next few years. It will grow to $9.71 billion in 2030 at a compound annual growth rate (CAGR) of 8.0%. The growth in the forecast period can be attributed to development of novel nephroprotective drugs, integration of ai-based diagnostics, expansion of home healthcare services, increasing geriatric population, rising investment in renal disease research. Major trends in the forecast period include rising adoption of advanced dialysis and renal support therapies, increasing focus on early diagnosis of acute kidney injury, growth in use of nephroprotective drug therapies, expansion of imaging and biopsy-based diagnostic techniques, increasing preference for home healthcare management for arf patients.

Global Acute Renal Failure (ARF) Market Segmentation

1) By Disease Type: Prerenal Acute Renal Failure, Renal Acute Renal Failure, Postrenal Acute Renal Failure 2) By Drug Type: Diuretics, Vasopressors, Erythropoiesis-Stimulating Agents (ESAS), Phosphate Binders, Calcium and Vitamin D Supplements, Antibiotics, Other Drugs 3) By Route of Administration: Oral, Intravenous 4) By End-Users: Clinics, Hospitals, Others End-Users Subsegments: 1) By Prerenal Acute Renal Failure: Hypovolemia, Decreased Cardiac Output, Renal Artery Stenosis 2) By Renal Acute Renal Failure: Acute Tubular Necrosis, Glomerulonephritis, Interstitial Nephritis 3) By Postrenal Acute Renal Failure: Obstructive Uropathy, Bladder Outlet Obstruction, Kidney Stones

What Is The Driver Of The Acute Renal Failure (ARF) Market?

The increasing prevalence of Chronic Kidney Diseases is expected to propel the growth of the acute renal failure (ARF) market going forward. Chronic kidney disease (CKD) refers to a long-term condition where the kidneys are damaged and can't filter blood properly. The increasing prevalence of chronic kidney disease (CKD) is due to rising rates of diabetes, hypertension, obesity, aging populations, and lifestyle-related factors worldwide. Acute renal failure, characterized by the sudden loss of kidney function, can act as a significant trigger or exacerbating factor for chronic kidney disease by causing lasting damage to kidney tissues, impairing filtration efficiency, and increasing the risk of progressive, long-term kidney dysfunction when not managed effectively. For instance, in June 2023, according to the report published by Kidney Research UK, a UK-based non-profit organization, currently, approximately 7.2 million people in the UK are living with chronic kidney disease, representing over 10% of the population. Of these, 3.25 million are in the advanced stages of the disease, while an additional 3.9 million are in the early stages. By 2033, the number of individuals affected by chronic kidney disease is projected to rise to 7.61 million. Therefore, the increasing prevalence of chronic kidney diseases is driving growth in the acute renal failure (ARF) industry.

Key Players In The Global Acute Renal Failure (ARF) Market

Major companies operating in the acute renal failure (arf) market are Pfizer Inc, Novartis AG, Baxter International Inc, Fresenius Medical Care AG and Co KGaA, Medtronic plc, Asahi Kasei Corporation, Astellas Pharma Inc, NIKKISO Co Ltd, NIPRO Corporation, Quark Pharmaceuticals Inc, AM Pharma BV, Sentien Biotechnologies, Angion Biomedica Corp, Alloksys Life Sciences BV, Theravance Biopharma, Kissei Pharmaceutical Co Ltd, Otsuka Pharmaceutical Co Ltd, B Braun Melsungen AG, Chiesi Farmaceutici SpA, Takeda Pharmaceutical Company Limited

Global Acute Renal Failure (ARF) Market Trends and Insights

Major companies operating in the acute renal failure (ARF) market are focusing on obtaining regulatory approvals for drugs to expand their reach and strengthen their position in the treatment of severe acute kidney injury (AKI). Regulatory approvals involve formal authorization from governmental or regulatory bodies for the marketing and public use of drugs, medical devices, or treatments. For instance, in February 2024, CalciMedica., a US-based clinical-stage biopharmaceutical company, received FDA approval for an IND application for a Phase 2 trial of Auxora to evaluate Auxora's efficacy in treating severe acute kidney injury (AKI) associated with acute hypoxemic respiratory failure (AHRF), a condition characterized by a high mortality rate. The KOURAGE trial is a randomized, double-blind, placebo-controlled study designed to enroll approximately 150 patients with Stage 2 and 3 acute kidney injury (AKI) who also have acute hypoxemic respiratory failure (AHRF), assessing the efficacy of Auxora over five daily doses by evaluating the number of days alive without the need for ventilators or dialysis up to 30 days post-treatment.

What Are Latest Mergers And Acquisitions In The Acute Renal Failure (ARF) Market?

In June 2023, Elicio Therapeutics Inc., a US-based biotechnology company, completed a merger with Angion Biomedica Corp. to enhance its pipeline of immunotherapies. With this merger, Elicio Therapeutics aims to strengthen its immunotherapy pipeline by leveraging Angion Biomedica's expertise and resources, enhancing the development of innovative treatments for various diseases, and accelerating the progress of novel therapies in the biotechnology sector. Angion Biomedica is a US-based biopharmaceutical company specializes in developing treatments for acute renal failure (ARF).

Regional Outlook

North America was the largest region in the acute renal failure (ARF) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Acute Renal Failure (ARF) Market?

The acute renal failure (ARF) market consists of revenues earned by entities by providing services such as dialysis treatment, emergency care, renal replacement therapies, post-acute care for kidney recovery, and hospital-based interventions. The market value includes the value of related goods sold by the service provider or included within the service offering. The acute renal failure (ARF) market also includes sales of dialysis equipment, normal saline, urine test kits, and urinary catheters. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Acute Renal Failure (ARF) Market Report 2026?

The acute renal failure (arf) market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the acute renal failure (arf) industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.